Monday, March 30, 2015 6:48:09 AM
Posted on March 30, 2015 by John Miller in Investing, Options Articles
Click For Link
Shares of Zogenix (NASDAQ:ZGNX) were the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totalling 28,195,078 shares, a growth of 6.1% from the February 27th total of 26,561,690 shares, Analyst Ratings Network.com reports. Based on an average daily trading volume, of 8,079,082 shares, the days-to-cover ratio is presently 3.5 days. Approximately 21.1% of the shares of the company are short sold.
A number of research firms have recently commented on ZGNX. Analysts at William Blair downgraded shares of Zogenix from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 11th. Separately, analysts at Brean Capital reiterated a “buy” rating on shares of Zogenix in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $3.00.
Zogenix (NASDAQ:ZGNX) opened at 1.34 on Monday. Zogenix has a one year low of $1.07 and a one year high of $3.10. The stock’s 50-day moving average is $1. and its 200-day moving average is $1.. The company has a market cap of $205.51 million and a price-to-earnings ratio of 22.33.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.13) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $14.90 million for the quarter. During the same quarter last year, the company posted ($0.13) earnings per share. Zogenix’s revenue was up 50.5% compared to the same quarter last year. Analysts expect that Zogenix will post $-0.37 EPS for the current fiscal year.
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM